|
Title
|
|
|
|
Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists JACC focus seminar
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Given the intersection between diabetes mellitus and cardiovascular disease (CVD), pharmacologic agents used to treat type 2 diabetes mellitus must show cardiovascular safety. Comorbid conditions, including heart failure and chronic kidney disease, are increasingly prevalent in patients with diabetes; therefore, they also play a large role in drug safety. Although biguanides, sulfonylurea, glitazones, and dipeptidyl peptidase 4 inhibitors have variable effects on cardiovascular events, sodium glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have consistently shown safety and reduction in cardiovascular events in patients with established CVD. These medications are becoming essential tools for cardioprotection for patients with diabetes and CVD. They may also have roles in primary prevention and renal protection. This paper will review the cardiovascular impact, adverse effects, and possible mechanisms of action of pharmacologic agents used to treat patients with type 2 diabetes. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of the American College of Cardiology. - New York, N.Y.
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2020
| |
|
ISSN
|
|
|
|
0735-1097
| |
|
DOI
|
|
|
|
10.1016/J.JACC.2020.02.056
| |
|
Volume/pages
|
|
|
|
75
:16
(2020)
, p. 1956-1974
| |
|
ISI
|
|
|
|
000531872400013
| |
|
Pubmed ID
|
|
|
|
32327107
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|